ADXN(ADXN)
ADXN
10/9/26
Addex Therapeutics (ADXN)
Friday
11:04 AM
ThesisThe company faces increasing pressure from emerging competitors and potential liquidity issues, which may dampen investor sentiment.
Revenue Outlook
What Moves the Stock
- 01Progress in clinical trials for ADX71149, particularly Phase II results
- 02Partnership announcements with major pharmaceutical companies
- 03Regulatory approvals or setbacks from health authorities
- 04Market sentiment towards biotechnology sector trends
- 05Research and development collaborations (100%)
- 06Increased focus on neurological disorders in drug development
- 07Growing interest in allosteric modulation as a therapeutic approach
FY2025 Snapshot
- Revenue
- $30.0K
- Rev. Growth
- -92.6%
- Gross Margin
- 100%
- Op. Margin
- -9391%
- Net Margin
- -22448%
- Net Income
- $-7M
- NI Growth
- -195%
- EPS
- $-6.88
- 1Y Return
- -66.9%
ADXN Chart
My Notes
- "Investors are cautious as the path to profitability remains uncertain amidst rising competition."
- Moat: The company's proprietary allosteric modulation technology provides a unique edge, though it is vulnerable to competitive innovations.
- growth - Investors looking for high-risk, high-reward opportunities in innovative drug development.
- Moderate - Rising interest rates could increase the cost of capital for funding R&D projects…
- Watch on earnings: Clinical trial success rates, Partnership deal flow, Cash runway (months until funding needed).
One Sentence Summary:
Addex Therapeutics: the story is balanced — progress in clinical trials for adx71149, particularly phase ii results.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers
